US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend Arexvy for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend Arexvy for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
Provider: View Press Release Type: Link Title: US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend Arexvy for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making | GSK Description: Committee recommendations mean over 55 million older adults in the US could have access to RSV vaccination for the first time
GSK announces extension of FDA review period for momelotinib
Provider: View Press Release Type: Link Title: GSK announces extension of FDA review period for momelotinib | GSK Description: GSK is confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review.
European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults
Provider: View Press Release Type: Link Title: European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults | GSK Description: Authorisation will help protect adults 60 years of age and older in 30 European countries from RSV disease for the first time
GSK receives US FDA file acceptance for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer
GSK receives US FDA file acceptance for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer
Provider: View Press Release Type: Link Title: GSK receives US FDA file acceptance for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer | GSK Description: Submission accepted for Priority Review
GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains
GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains
Provider: View Press Release Type: Link Title: GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains | GSK Description: GSK today presented preliminary positive results from the phase III trial
